Medtronic plc

Medtronic plc

MDTNYSE / NASDAQHealthcareLarge cap

$99.94-$0.67 (-0.7%)

Last close · Data as of Nov 20, 2026

Market cap
$105.2B
P/E
22.6x
EV / EBITDA
14.3x
Revenue
$33.5B
Net margin
13.9%
ROCE
8.3%

+0.6% over the last year

Medtronic plc price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+5.6%
3M
+8.3%
6M
+27.9%
1Y
+0.6%
5Y
-14.7%

52-week range

Day change -$0.67 (-0.7%) from $101 to $100 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MDT, bought on each weekday since 2021.

News & filings

What Medtronic filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernReturn on equity of 9.7% against a peer median of 9.9%.

Strengths (1)

  • Operating margin of 19.5% against a peer median of 17.5%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.

Read moreShow less

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Sector
Healthcare
Shares outstanding
1.28B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$105.2B
P/E
22.6x
P/B
2.2x
EV / EBITDA
14.3x
EV / Sales
3.9x
P/S
3.1x
52-week high
$105.35
52-week low
$73.75

Profitability

Operating margin
19.5%
Net margin
13.9%
EBITDA margin
27.5%
ROE
9.7%
ROCE
8.3%
ROA
5.1%
Asset turnover
0.37

Growth

Revenue
$33.5B
Revenue growth, 1Y
3.6%
Revenue CAGR, 3Y
1.9%
Net profit growth, 1Y
26.8%
Free cash flow
$5.2B

Solvency

Current ratio
1.85
Debt / Equity
0.59
Debt / Assets
0.31
CFO / Net profit
1.51
Cash / Market cap
2.1%

Where the revenue went

Of every $100 of FY2025 revenue, $14 was left as net income.

Medtronic plc income statement flow, FY2025
Medtronic plc income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$11.6B
RevenueGross profit$21.9B
Gross profitResearch and development$2.7B
Gross profitSelling, general and administrative$10.8B
Gross profitOther operating expenses$1.8B
Gross profitOperating income$6.5B
Operating incomePretax income$5.6B
Operating incomeInterest and other expense$912.0M
Pretax incomeTax and other$966.0M
Pretax incomeNet income$4.7B

Revenue and net profit

Revenue grew 3.6% in FY2025; net profit is the dashed line.

Medtronic plc revenue and net profit by fiscal year
Medtronic plc revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$31.7B$5.0B
FY2023$31.2B$3.8B
FY2024$32.4B$3.7B
FY2025$33.5B$4.7B

Cash flows

FY2025: $7.0B from operations, $5.2B free after investment (dashed).

Medtronic plc operating and free cash flow by fiscal year
Medtronic plc operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$7.3B$6.0B
FY2023$6.0B$4.6B
FY2024$6.8B$5.2B
FY2025$7.0B$5.2B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$33.5B+3.6%1Y
EBITDA
$9.2B+12.4%1Y
Net profit
$4.7B+26.8%1Y
Cash from operations
$7.0B+3.8%1Y
Free cash flow
$5.2B-0.3%1Y
Revenue CAGR, 3Y
1.9%
Net profit CAGR, 3Y
-2.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$33.5B$9.2B$4.7B$5.2B9.7%+3.6%+26.8%

Monthly returns

Month-by-month returns of MDT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$91.7B
Liabilities$43.4B
Equity$48.3B
Paid-in capital$20.8B
Retained earnings$31.5B
Minority interest$232.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MDT highlighted.

P/E against peers

MDT trades at 22.6x earnings against a peer median of 23.7x.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Medtronic plcMDTthis company$105.2B22.6x2.2x9.7%14.3x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Stryker CorporationSYK$115.5B35.6x5.2x14.5%20.2x
Vertex Pharmaceuticals IncorporatedVRTX$112.1B28.4x6.0x21.2%22.4x
McKesson CorporationMCK$91.0B19.1x-41.9x-219.2%13.3x
Elevance Health, Inc.ELV$88.9B15.7x2.0x12.9%—
HCA Healthcare, Inc.HCA$80.3B11.8x-13.3x-112.6%8.2x
Peer median—23.7x2.3x9.9%19.5x

Year-to-date ROI

MDT since 1 January, against earlier years.

Historical volatility

MDT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Medtronic plc operating margin by fiscal year
Medtronic plc operating margin by fiscal year
DateOperating margin
FY202218.6%
FY202318.7%
FY202417.1%
FY202519.5%
LineFY2025
Cost of revenueCost Of Revenue$11.6B
Gross profitGross Profit$21.9B
Operating expensesOperating Expense$15.4B
Research and developmentResearch And Development$2.7B
Selling, general and administrativeSelling General And Administration$10.8B
Other operating expensesOther Operating Expenses-$23.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$1.8B
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$1.8B
Amortization$1.8B
Amortisation of intangiblesAmortization Of Intangibles Income Statement$1.8B
Total expensesTotal Expenses$27.0B
Pretax incomePretax Income$5.6B

Learn while you research

Academy chapters picked for Medtronic plc and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →